Regulatory approval is the entry ticket; procurement is where revenue actually happens. Mapping the right tender, distributor, and KOL path per market is what turns a launch into a P&L.
One of the most common — and most expensive — assumptions in MedTech is that regulatory approval will be quickly followed by revenue. In APAC, the gap between approval and adoption can be 12 to 24 months, and most of that time is spent inside procurement: tenders, formularies, distributor enablement, and KOL adoption. Understanding the pathway in each market is what separates a launch from a P&L.
Public vs private — two different clocks
Public systems (HA in Hong Kong, public hospitals in Taiwan, tertiary hospitals in mainland China) buy through structured tenders with annual or biennial cycles. Miss the cycle and you wait. Private hospitals buy on a clinical-pull basis: a champion physician, a procurement committee, a contract.
- Public: high volume, lower margin, slow start, predictable once in.
- Private: higher margin, faster start, more dependent on individual relationships.
A serious launch plan engages both in parallel from day one.
Choosing a distributor
The instinct is to pick the largest distributor in market. The better question is: which distributor already calls on the 30 hospitals where my device matters? A focused, mid-sized distributor with the right accounts will out-perform a national giant whose reps prioritise other lines.
The distributor decision is not about size — it is about call-point overlap, clinical credibility in your indication, and willingness to invest in training.
KOL engagement: start before approval
By the time a device is approved, the KOLs should already know it, ideally through clinical exposure during the trial or a structured advisory programme. Approval-day is too late to begin relationships — it is the day to activate them.
A simple KOL framework
- Identify 8–12 KOLs per market across the relevant subspecialties.
- Engage through advisory boards, site visits, and (where appropriate) trial participation.
- Enable with peer-reviewed data, training materials, and conference platforms.
- Measure influence not by social presence but by referral and procurement impact.
Reimbursement is part of access
In Taiwan, NHIA reimbursement decisions can make or break adoption. In mainland China, DRG/DIP reform is reshaping how hospitals think about device cost. In Hong Kong, the HA's special drug and device mechanisms matter more than list price. Treat reimbursement as a parallel workstream from the start of regulatory planning, not a follow-on.
Common launch mistakes
- Launching the same playbook in HK, TW and CN as if they were one market.
- Signing exclusive distribution before validating the call-point fit.
- Waiting for approval to start KOL conversations.
- Treating reimbursement as a finance problem rather than a market-access problem.
What to do next
The practical next step before a launch is a market-by-market access map: target accounts, tender calendar, distributor shortlist, KOL plan, and reimbursement assumptions on a single page per country. Built once, kept live, and reviewed quarterly, it is the closest thing to an APAC launch playbook that survives contact with reality.
